Compare CRNT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNT | TLSI |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.6M | 250.0M |
| IPO Year | 2000 | 2020 |
| Metric | CRNT | TLSI |
|---|---|---|
| Price | $2.05 | $4.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.83 | ★ $10.40 |
| AVG Volume (30 Days) | 310.1K | ★ 316.9K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $45,151,000.00 |
| Revenue This Year | $9.08 | $17.65 |
| Revenue Next Year | $6.40 | $40.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $1.85 | $2.20 |
| 52 Week High | $3.29 | $7.95 |
| Indicator | CRNT | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 34.71 |
| Support Level | $2.03 | $3.64 |
| Resistance Level | $2.17 | $4.48 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 28.95 | 6.57 |
Ceragon Networks Ltd is a wireless transport specialist, providing wireless connectivity solutions to markets globally across various industries, including wireless (mobile) network service providers and private networks, enabling them to build new networks and evolve networks towards 4G and 5G services. Its portfolio mainly comprises the IP-20 and IP-50 product series, including integrated multi-technology radio units operating across frequencies from 4 GHz to 86 GHz, as well as single-radio devices used for wireless data transport. Additionally, the company offers turnkey services including: network and radio planning, site survey, installation, network auditing and optimization, and more. Geographically, it derives maximum revenue from India, followed by North America and other regions.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.